This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Randomized Controlled Trial  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic

The SURVIVE Randomized Trial

Alexandre Mebazaa, MD, PhD; Markku S. Nieminen, MD, PhD; Milton Packer, MD; Alain Cohen-Solal, MD, PhD; Franz X. Kleber, MD; Stuart J. Pocock, PhD; Roopal Thakkar, MD; Robert J. Padley, MD; Pentti Põder, MD, PhD; Matti Kivikko, MD, PhD; for the SURVIVE Investigators

JAMA. 2007;297:1883-1891.

Context  Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival.

Objective  To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival.

Design, Setting, and Patients  The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004.

Interventions  Intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).

Main Outcome Measure  All-cause mortality at 180 days.

Results  All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group.

Conclusion  Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes.

Trial Registration  clinicaltrials.gov Identifier: NCT00348504

Author Affiliations: Departments of Anesthesiology (Dr Mebazaa), Critical Care Medicine (Dr Mebazaa), and Cardiology (Dr Cohen-Solal), Université Paris Diderot and Hospital Lariboisière AP-HP, Paris, France; Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland (Dr Nieminen); Department of Clinical Sciences, University of Texas Southwestern Medical School, Dallas (Dr Packer); Department of Internal Medicine, Charité Medical School, Berlin, Germany (Dr Kleber); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, England (Dr Pocock); Cardiovascular Clinical Research, Abbott Laboratories, Abbott Park, Ill (Drs Thakkar and Padley); and Cardiology Unit, Clinical Research and Development, Orion Pharma, Espoo, Finland (Drs Põder and Kivikko).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sodium nitroprusside for advanced low-output heart failure.
Mullens et al.
J Am Coll Cardiol 2008;52:200-207.
ABSTRACT | FULL TEXT  

Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure
Gheorghiade et al.
J Am Coll Cardiol 2008;51:2276-2285.
ABSTRACT | FULL TEXT  

Evoked Changes in Cardiovascular Function in Rats by Infusion of Levosimendan, OR-1896 [(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], Dobutamine, and Milrinone: Comparative Effects on Peripheral Resistance, Cardiac Output, dP/dt, Pulse Rate, and Blood Pressure
Segreti et al.
J. Pharmacol. Exp. Ther. 2008;325:331-340.
ABSTRACT | FULL TEXT  

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Pang et al.
Eur Heart J 2008;29:816-824.
ABSTRACT | FULL TEXT  

Approach to Hemodynamic Shock and Vasopressors
Herget-Rosenthal et al.
CJASN 2008;3:546-553.
FULL TEXT  

Cardiogenic Shock: Current Concepts and Improving Outcomes
Reynolds and Hochman
Circulation 2008;117:686-697.
FULL TEXT  

Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
Banfor et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H238-H248.
ABSTRACT | FULL TEXT  

JournalScan
Lindsay
Heart 2007;93:1159-1160.
FULL TEXT  

Can Levosimendan Help in Acute Decompensated Heart Failure?
Journal Watch Cardiology 2007;2007:2-2.
FULL TEXT